Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.45 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 8/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25691118 | 0.88 | CRBN (0.54) | CRBNDDB1HPGDS | |
| SCHEMBL25690970 | 0.83 | CRBN (0.63) | CRBNDDB1IRAK4 | |
| SCHEMBL25690999 | 0.81 | CRBN (0.66) | CRBNDDB1HPGDSBTK | |
| SCHEMBL25691397 | 0.81 | CRBN (0.45) | CRBNDDB1HTR1A | |
| SCHEMBL23117907 | 0.77 | CRBN (0.57) | CRBNDDB1HPGDSIRAK1IRAK4 | |
| SCHEMBL29822127 | 0.77 | CRBN (0.57) | CRBNDDB1HPGDSIRAK1IRAK4 | |
| SCHEMBL26815156 | 0.76 | CRBN (0.61) | CRBNDDB1HPGDSIRAK1IRAK4 | |
| SCHEMBL23133944 | 0.76 | CRBN (0.56) | CRBNDDB1HPGDS | |
| SCHEMBL30144779 | 0.76 | CRBN (0.71) | CRBNDDB1HPGDS | |
| SCHEMBL25075064 | 0.76 | CRBN (0.71) | CRBNDDB1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885DDB1 1112/4885HPGDS 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.